Healthcare and Life Sciences

On March 10, 2026, Elsevier, a global leader in advanced information and decision support and part of RELX, announced it has entered into a definitive agreement to acquire Mytonomy, a leader in video-based patient engagement solutions that will complement Elsevier’s Clinical Solutions portfolio. Cravath is representing RELX in connection with the transaction.

On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.

On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.

Cravath represented the underwriters in connection with the $3 billion registered senior notes offering of Cencora, Inc., a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Proceeds of the offering were used to repay, in full, the term loan facility used to finance Cencora, Inc's acquisition of OneOncology. The transaction closed on February 13, 2026.

Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $5.5 billion of credit facilities made available to Cencora, Inc., as part of the financing transactions undertaken in connection with its acquisition of OneOncology, a physician‑led national platform empowering independent medical specialty practices rooted in oncology. Cencora, Inc. is a leading global pharmaceutical sourcing and distribution services company. The credit facilities consisted of a $1.5 billion term loan facility, a $3.0 billion term loan facility and a $1.0 billion commitment increase under an existing revolving credit facility. The transaction closed on January 12, 2026.

On February 12, 2026, Cravath partners D. Scott Bennett, Elad Roisman, Nicholas A. Dorsey and Sasha Rosenthal‑Larrea were profiled in Lawdragon’s “Lawyer Limelight” series in connection with the Firm’s work for “companies at the forefront of innovation in digital assets, AI, fintech, biotech, media and emerging technologies.”

Cravath partner Margaret T. Segall and of counsel Nicole M. Peles authored a chapter entitled “Navigating the Complex Landscape of Merger Remedies in Dynamic Industries: Insights from Antitrust Authorities” for Global Competition Review’s “Merger Remedies Guide – Sixth Edition,” published on October 31, 2025. The chapter discusses common types of merger remedies, the challenges they face in dynamic industries including the pharmaceutical/biotechnology and technology sectors and the different approaches antitrust authorities use to address them.  

On November 10, 2025, Cravath published the latest edition of its Quarterly Review, which provides insight into practical points, key takeaways and relevant developments across the M&A, activism, restructuring, regulatory and corporate governance landscape. This edition covers:

On September 18, 2025, Cravath published the fifth edition of its Cravath Data Privacy and Security Review newsletter. The Review provides an overview of recent U.S. state and federal legislative and regulatory developments, alongside U.S. and global enforcement trends and takeaways, in data privacy and cybersecurity for the first six months of 2025. It first presents an update on emerging and existing privacy and security legislation at the federal level, including amendments to the Children’s Online Privacy Protection Rule, then highlights notable legislative developments at the state level across the country. This edition also explores the heightened focus on cybersecurity- and privacy‑related enforcement at federal agencies, including the Federal Trade Commission, Securities and Exchange Commission and Department of Justice, and provides global enforcement updates from the European Union and China.

On September 5, 2025, LMG Life Sciences honored Cravath at the publication’s 2025 Americas Awards, which recognize “top firms, attorneys and in‑house counsel for their work in the life sciences industry over the past year.” The Firm was honored with an Impact Deal of the Year award for its representation of Johnson & Johnson in its $14.6 billion acquisition of Intra Cellular Therapies, Inc.